Mazdutide vs Tirzepatide: How Do These Two Treatments Compare?

You've read the trial headlines, here's what they actually mean for someone in the UK right now

Imagine you've spent twenty minutes reading about a drug called mazdutide after an algorithm surfaced it alongside tirzepatide. The coverage is exciting: phase II and phase III data from Chinese trials, meaningful weight-loss numbers, a mechanism that activates both GLP-1 and glucagon receptors rather than GLP-1 and GIP. Then you try to find where you can actually get it, and the trail goes cold.

That experience is common, and the reason is straightforward. Mazdutide (also known by the code OIC-401, developed by Innovent Biologics) has been studied primarily in Chinese populations and has not received approval from the MHRA or any European regulatory body for weight management. No UK pharmacy (registered or otherwise) can legally dispense it. The clinical picture is therefore interesting but not yet actionable for a patient in Britain.

Tirzepatide sits in an entirely different position. The MHRA granted it a UK marketing authorisation for weight management; NICE assessed it favourably in technology appraisal TA1026, published December 2024; and it is available now through regulated private clinics and pharmacies, including nume. If you're reading this comparison because you want to make a decision today, that distinction matters more than any head-to-head trial data between the two molecules. You can read more about how tirzepatide works as a treatment on the Mounjaro overview.

What the science actually says: mechanism and weight-loss data compared

Tirzepatide acts on two receptors: GLP-1 and GIP. Both slow gastric emptying and reduce appetite; GIP has additional effects on fat metabolism and may improve tolerability. In the SURMOUNT-1 trial, involving around 2,500 adults with obesity, participants on 15mg tirzepatide lost an average of roughly 20–21% of body weight over 72 weeks, results that the NEJM paper describes in full and that NICE used as the basis for TA1026's recommendation.

Mazdutide targets GLP-1 and glucagon receptors instead. Glucagon typically raises blood glucose, but when co-activated with GLP-1, it appears to increase energy expenditure and drive fat oxidation. Phase III data presented from trials in China showed competitive weight-loss figures, though direct comparison is complicated by differences in trial design, population, duration and background lifestyle support. No peer-reviewed head-to-head trial between mazdutide and tirzepatide exists.

The comparison that does have trial-level evidence is tirzepatide versus semaglutide 2.4mg (Wegovy). SURMOUNT-5, a 72-week open-label head-to-head in adults with obesity and no diabetes, showed tirzepatide produced greater average weight reduction. If you're interested in that particular comparison, our page on GLP-1 versus tirzepatide covers the mechanistic differences in more depth. And for those curious about how retatrutide (a triple agonist further along in its own trial programme) fits into this picture alongside tirzepatide, the retatrutide vs tirzepatide page is worth reading.

Where mazdutide, retatrutide and other pipeline molecules sit on the timeline

There is genuine scientific interest in molecules beyond tirzepatide. Retatrutide (a GLP-1, GIP and glucagon triple agonist) and pemvidutide (a GLP-1/glucagon dual agonist similar in profile to mazdutide) are both in advanced trials. The comparison between mazdutide and tirzepatide vs retatrutide is one researchers are actively discussing, even if regulators haven't been asked to make a call yet. Our reta vs tirzepatide page covers what the phase II data shows for retatrutide.

For a UK patient, the practical timeline looks like this: tirzepatide is licensed now; semaglutide (Wegovy) is licensed now; everything else is in development. Regulatory review, even for a compelling molecule, typically takes years from the point of filing. Mazdutide has not yet submitted to the MHRA.

The NHS England overview of weight management medicines is a useful reference for understanding where the licensed options sit within the broader treatment landscape, and for seeing just how much infrastructure sits behind a medicine that has made it through. If none of the currently licensed treatments suit you, that's a conversation to have with a prescriber, not a reason to seek an unlicensed compound. The pemvidutide vs tirzepatide page applies the same framework to a comparable molecule.

Which of these can a UK prescriber actually offer you, and how does that decision get made?

A GPhC-registered prescriber working in a regulated UK service can prescribe tirzepatide for weight management when clinical criteria are met: broadly, a BMI of 30 or above, or 27 or above alongside a weight-related health condition. Lower thresholds apply for some ethnic backgrounds under UK guidance. BMI alone is not a guarantee of approval, the full clinical picture matters, including any conditions that might contraindicate treatment.

Mazdutide cannot be offered. Full stop. That isn't a policy position specific to any one clinic; it's the legal position in the UK for any medicine that hasn't received MHRA authorisation. Importing or dispensing it without a licence would be unlawful, regardless of what overseas trial data shows.

At nume, a named prescriber (not an automated system) reviews every consultation the same day. For tirzepatide specifically, that review includes a live weight verification and photo-ID check, consistent with our GPhC registration. The pen you'd receive arrives via DPD the next working day, tracked to your door in a plain box. Which treatment is right for you is a clinical decision, not a content one, and it's the kind of decision our prescribers make in consultation with you, not for you from a distance. You can find pricing context for tirzepatide on our Mounjaro price comparison page, or check your eligibility directly through our treatment consultation.